-+ 0.00%
-+ 0.00%
-+ 0.00%

Pliant Therapeutics Presents RNA Delivery Platform Targeting Skeletal and Cardiac Muscle

PUBT·11/12/2026 21:18:45
Listen to the news
Pliant Therapeutics Presents RNA Delivery Platform Targeting Skeletal and Cardiac Muscle
  • Pliant Therapeutics is advancing its integrin-targeted RNA delivery programs toward investigational new drug applications for selected neuromuscular diseases and rare cardiomyopathies.
  • PLN-662 demonstrated skeletal and cardiac muscle target gene knockdown in mice and nonhuman primates following subcutaneous dosing.
  • PLN-753 achieved durable, selective skeletal muscle gene knockdown in mice following a single low subcutaneous dose.
  • Combined with tirzepatide, PLN-753-siMSTN preserved lean mass and enhanced fat loss in a preclinical study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.